Cargando…
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or che...
Autores principales: | Collignon, A., Hospital, M. A., Montersino, C., Courtier, F., Charbonnier, A., Saillard, C., D’Incan, E., Mohty, B., Guille, A., Adelaïde, J., Carbuccia, N., Garnier, S., Mozziconacci, M. J., Zemmour, C., Pakradouni, J., Restouin, A., Castellano, R., Chaffanet, M., Birnbaum, D., Collette, Y., Vey, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266815/ https://www.ncbi.nlm.nih.gov/pubmed/32488055 http://dx.doi.org/10.1038/s41408-020-0330-5 |
Ejemplares similares
-
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
por: Collette, Y, et al.
Publicado: (2015) -
Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification
por: Cervera, N, et al.
Publicado: (2017) -
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022) -
Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial
por: Sabatier, Renaud, et al.
Publicado: (2022) -
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
por: Brecqueville, M, et al.
Publicado: (2011)